Qualio
👤 Robert Fenton (Ex-Pfizer quality man and Cork pharmacist. He lived the audit-trail pain the FDA forces, then built the QMS for it.)🌐 siteLinkedIn
Life-sci firms must run an audited QMS by law. Qualio is the one startups adopt before their first FDA audit.
Will it work? · our read
Mandated demand. The regulation, not marketing, creates the need. Qualio's real bet is winning startups early and holding them through every audit as they scale.
01How the money moves
Startup must pass an FDA/ISO audit to ship
→
Adopts Qualio as its cloud QMS and document control
→
Pays annual per-seat subscription, renews to stay audit-ready
02The numbers
700+ customersStatedrevenue never disclosed
2026
Customer counts are Qualio's own; the ARR figure is a Latka estimate the company has not confirmed.
700+ regulated customers in 80+ countries. Revenue undisclosed; Latka est. about $22M ARR (2024).
🔒
You have the verdict. Members get the work behind it.
- The CENTS scorecard — where it's strong, where it's soft
- The founder's key move, and the counter-move
- How it could die — the evidence, and how sure we are
- The case against our own call
- A 🚀 launchpad prompt — the case, as a plan for your business
We rate our own confidence — and argue against ourselves. Nobody else in this category does.
Sources always public on all 552 cases · cancel anytime · 14-day refund
See a full teardown, free → ImportYetiSourcesSources last checked 19 August 2026
Qualio homepage: "Trusted by 700+ highly regulated customers", "500+ companies in 80+ countries" (2026)Latka: Qualio est. about $22M ARR (2024), $19.3M (2023) — third-party estimateThinkBusiness: Robert Fenton, from Pfizer quality to Qualio (founder story)Forbes: Qualio raises $50M Series B led by Tiger Global (2021)FDA: Quality System Regulation / QMSR (the mandate)
Headline is first-party: Qualio's own site states "Trusted by 700+ highly regulated customers" across "80+ countries" (fetched 2026), the biggest real number the company publishes. Qualio does not disclose revenue; Latka estimates about $22M ARR (2024) and $19.3M (2023), which the company has not confirmed — and Latka's funding figure ($16.3M) is demonstrably wrong (the $50M Series B from Tiger Global in 2021 is documented by Forbes), so its ARR is treated as a soft third-party estimate, not headlined. Founder background from ThinkBusiness and Medical Alley interviews. Headcount reportedly declined from about 156 (2023) to about 117 (2026) per Latka, consistent with post-2022 SaaS tightening. The regulation moat (FDA QSR/QMSR, ISO 13485, EU MDR, 21 CFR Part 11) is real and verifiable at fda.gov. verified:true refers to the first-party customer count on qualio.com, not to a revenue figure — revenue remains undisclosed. We never score you.